OraSure Technologies, Inc. (OSUR): Price and Financial Metrics
GET POWR RATINGS... FREE!
OSUR POWR Grades
- Value is the dimension where OSUR ranks best; there it ranks ahead of 85.55% of US stocks.
- The strongest trend for OSUR is in Quality, which has been heading down over the past 179 days.
- OSUR's current lowest rank is in the Growth metric (where it is better than 1.04% of US stocks).
OSUR Stock Summary
- OSUR's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 11.43% of US stocks.
- With a year-over-year growth in debt of 100.29%, Orasure Technologies Inc's debt growth rate surpasses 89.89% of about US stocks.
- In terms of twelve month growth in earnings before interest and taxes, Orasure Technologies Inc is reporting a growth rate of 163.68%; that's higher than 87.72% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Orasure Technologies Inc are SMWB, FARO, INTZ, APPN, and MASS.
- OSUR's SEC filings can be seen here. And to visit Orasure Technologies Inc's official web site, go to www.orasure.com.
OSUR Valuation Summary
- In comparison to the median Healthcare stock, OSUR's price/sales ratio is 69.16% lower, now standing at 3.5.
- OSUR's EV/EBIT ratio has moved up 62.2 over the prior 243 months.
- OSUR's price/sales ratio has moved down 11.2 over the prior 243 months.
Below are key valuation metrics over time for OSUR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| OSUR | 2021-08-31 | 3.5 | 1.9 | 148.5 | 25.9 |
| OSUR | 2021-08-30 | 3.5 | 1.9 | 147.6 | 25.7 |
| OSUR | 2021-08-27 | 3.4 | 1.9 | 143.6 | 24.9 |
| OSUR | 2021-08-26 | 3.4 | 1.9 | 143.6 | 24.9 |
| OSUR | 2021-08-25 | 3.4 | 1.9 | 145.2 | 25.2 |
| OSUR | 2021-08-24 | 3.4 | 1.9 | 143.7 | 24.9 |
OSUR Growth Metrics
- Its 3 year net income to common stockholders growth rate is now at 83.4%.
- Its 3 year net cashflow from operations growth rate is now at 17.98%.
- Its year over year price growth rate is now at -45.55%.
The table below shows OSUR's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 233.674 | -35.382 | -22.998 |
| 2021-09-30 | 232.961 | -18.987 | -10.745 |
| 2021-06-30 | 227.055 | 4.519 | 5.31 |
| 2021-03-31 | 198.707 | -1.085 | -3.82 |
| 2020-12-31 | 171.721 | 5.807 | -14.922 |
| 2020-09-30 | 158.534 | 1.162 | -14.344 |
OSUR's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- OSUR has a Quality Grade of C, ranking ahead of 49.18% of graded US stocks.
- OSUR's asset turnover comes in at 0.501 -- ranking 93rd of 186 Medical Equipment stocks.
- MMSI, MMM, and ICUI are the stocks whose asset turnover ratios are most correlated with OSUR.
The table below shows OSUR's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.501 | 0.605 | 0.127 |
| 2021-03-31 | 0.450 | 0.624 | 0.073 |
| 2020-12-31 | 0.420 | 0.593 | -0.019 |
| 2020-09-30 | 0.414 | 0.590 | -0.036 |
| 2020-06-30 | 0.409 | 0.579 | 0.016 |
| 2020-03-31 | 0.466 | 0.594 | 0.096 |
OSUR Price Target
For more insight on analysts targets of OSUR, see our OSUR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $13.25 | Average Broker Recommendation | 1.71 (Moderate Buy) |
OSUR Stock Price Chart Interactive Chart >
OSUR Price/Volume Stats
| Current price | $4.33 | 52-week high | $13.57 |
| Prev. close | $4.51 | 52-week low | $4.17 |
| Day low | $4.17 | Volume | 1,451,200 |
| Day high | $4.71 | Avg. volume | 627,892 |
| 50-day MA | $6.32 | Dividend yield | N/A |
| 200-day MA | $8.79 | Market Cap | 313.73M |
OraSure Technologies, Inc. (OSUR) Company Bio
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company was founded in 1979 and is based in Bethlehem, Pennsylvania.
Latest OSUR News From Around the Web
Below are the latest news stories about Orasure Technologies Inc that investors may wish to consider to help them evaluate OSUR as an investment opportunity.
OraSure Technologies Reports 4Q21 Revenue of $63.6 Million; InteliSwab® Production Scales UpTotal 2021 revenue of $233.7 million, up 36% year-over year InteliSwab® receives emergency use authorization expansion and demonstrates accurate detection of Omicron variant InteliSwab® revenue of $14.7 million in Q4, up 92% sequentially Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET BETHLEHEM, Pa., Feb. 23, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbio |
OraSure Technologies, Inc. 2021 Fourth Quarter Earnings Conference Call Wednesday, February 23, 2022, 5:00 p.m. ETBETHLEHEM, Pa., Feb. 16, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, February 23, 2022. |
OraSure Technologies files for $300M mixed shelf offeringOraSure Technologies has filed for a $300M mixed shelf offering. |
InteliSwab® COVID-19 Rapid Tests Receive U.S. FDA Authorization for Pediatric Use and Company Launches New InteliSwab® Connect Reporting AppData Demonstrates InteliSwab ® is Accurate, Easy to Use, and Well Accepted by Children BETHLEHEM, Pa., Jan. 31, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR ), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its InteliSwab ® COVID-19 rapid tests have been authorized by the U.S. Food and Drug Administration (FDA) for use in children ages 2 to 14. InteliSwab ® was previously authorized for use in adults and in children 15 to 17 when administered by an adult. As part of its submission to the FDA for this label expansion, the Company conducted studies to evaluate the performance of the test in a pediatric population, as well as studies to evaluate usability and tolerability by children. From a combine... |
OraSure said its rapid COVID-19 tests can now be used in childrenShares of OraSure Technologies Inc. gained 2.2% in premarket trading on Monday after the company said its COVID-19 rapid tests have now been authorized for children between the ages of 2 and 14 years old. The tests had previously received emergency use authorization from the Food and Drug Administration for use in teens and adults. OraSure's stock is down 43.0% over the past year, while the broader S&P 500 is up 18.7%. |
OSUR Price Returns
| 1-mo | -33.38% |
| 3-mo | -44.20% |
| 6-mo | -54.56% |
| 1-year | -53.64% |
| 3-year | -47.26% |
| 5-year | -70.82% |
| YTD | -50.17% |
| 2021 | -17.90% |
| 2020 | 31.82% |
| 2019 | -31.25% |
| 2018 | -38.07% |
| 2017 | 114.81% |
Continue Researching OSUR
Here are a few links from around the web to help you further your research on Orasure Technologies Inc's stock as an investment opportunity:Orasure Technologies Inc (OSUR) Stock Price | Nasdaq
Orasure Technologies Inc (OSUR) Stock Quote, History and News - Yahoo Finance
Orasure Technologies Inc (OSUR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...